Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY: BMY )

65.31 +0.15 (+0.23%)
Official Closing Price Updated: 4:10 PM EDT, Jun 8, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,995,436
Open 65.34
Bid (Size) 65.30 (10)
Ask (Size) 65.46 (1)
Prev. Close 65.16
Today's Range 65.06 - 65.61
52wk Range 63.07 - 81.44
Shares Outstanding 2,222,113,553
Dividend Yield 3.00%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Bristol Myers Squibb Receives U.S. FDA Approval of New State-of-the-Art Cell Therapy Manufacturing Facility in Devens, Massachusetts
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb to Report Results for Second Quarter 2023 on July 27, 2023
From Bristol Myers Squibb
Via Business Wire

Performance

YTD
-9.62%
-9.62%
1 Month
-4.53%
-4.53%
3 Month
-2.94%
-2.94%
6 Month
-18.29%
-18.29%
1 Year
-14.73%
-14.73%

More News

Read More
Looking At Bristol-Myers Squibb's Recent Unusual Options Activity
Via Benzinga
Bristol Myers' Opdivo/Chemo Shows Durable Results At Four Years In Lung Cancer Patients
Via Benzinga
Is Bristol Myers Squibb a Top Dividend Stock?
Via The Motley Fool
Bristol Myers' CAR T Cell Therapy Shows Deep, Durable Efficacy In Blood Cancer Patients
Via Benzinga
Pharmaceutical Giant Merck Challenges Inflation Reduction Act over Medicare Drug Pricing, Calls It 'Extortion'
Via Benzinga
Chipotle, Bristol-Myers Squibb, Corteva And A Healthcare Giant On CNBC's 'Final Trades'
Via Benzinga
Four-Year Outcomes from Phase 3 CheckMate -9LA Trial Show Durable, Long-Term Survival with Opdivo (nivolumab) Plus Yervoy (ipilimumab) with Two Cycles of Chemotherapy for Patients with Metastatic Non-Small Cell Lung Cancer
From Bristol Myers Squibb
Via Business Wire
Bristol-Myers Squibb Unusual Options Activity
Via Benzinga
Biotechs Zeroing In on Developing Breakthrough Therapeutics for Metastatic Breast Cancer
Via FinancialNewsMedia
Exposures COVID-19
3 Dividend Stocks You Can Buy Without Any Hesitation
Via The Motley Fool
The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree
Via Investor's Business Daily
BioNTech Surges On This Promising Update In Its Bid To Take On Bristol Myers In Lung Cancer Treatment
Via Investor's Business Daily
3 Top Stocks That Just Went on Sale
Via The Motley Fool
Bristol Myers Squibb to Participate in Upcoming Investor Conferences
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb to Hold R&D Day on September 14
From Bristol Myers Squibb
Via Business Wire
Iovance Biotherapeutics Spikes on Melanoma BLA FDA Application
Via MarketBeat
Topics Death
Exposures Death Product Safety
Bristol Myers Squibb to Present Late-Breaking Data for Breyanzi (lisocabtagene maraleucel) in Relapsed or Refractory Follicular Lymphoma and Mantle Cell Lymphoma at 2023 International Conference on Malignant Lymphoma
From Bristol Myers Squibb
Via Business Wire
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Repotrectinib for the Treatment of Patients with Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer
From Bristol Myers Squibb
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) with Chemotherapy as Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer at High Risk of Recurrence in Patients with Tumor Cell PD-L1 Expre...
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb’s Breyanzi (lisocabtagene maraleucel) is First and Only CAR T to Deliver Deep and Durable Efficacy in Pivotal Multicenter Trial in Relapsed or Refractory Chronic Lymphocytic Leukemia, Based on Data Presented at ASCO 2023
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb to Present First Results at ASCO and EHA from Phase 3 COMMANDS Study of Reblozyl® (luspatercept-aamt) in First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS)
From Bristol Myers Squibb
Via Business Wire
Mirati's Sitravatinib Flunks Phase 3 Combo Therapy Study In Type Of Lung Cancer Setting
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.